Recent research have centered on the convergence of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine communication. While GLP stimulators are widely employed for treating type 2 diabetes, their emerging consequences on reward circuits, specifically governed by dopamine pathways,